LAWRENCE, Mass., May 10, 2012 /PRNewswire via COMTEX/ -- NxStage Medical, Inc. /quotes/zigman/98059/quotes/nls/nxtm NXTM -2.96% , a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, will participate in the following schedule of investor conferences. A webcast of the event will be made available at http://ir.nxstage.com/ at the time of each conference.

Jefferies 2012 Global Healthcare Conference New York, NY Tuesday, June 5, 20121:30 p.m. ET

William Blair 2012 Growth Stock Conference Chicago, IL Four Seasons Hotel Tuesday, June 12, 2012 2:10 p.m. CT

About NxStage Medical

NxStage Medical, Inc. /quotes/zigman/98059/quotes/nls/nxtm NXTM -2.96% is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com .

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Mr. Burbank's plans to present at these conferences. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq. Investor Relations This e-mail address is being protected from spambots. You need JavaScript enabled to view it

SOURCE NxStage Medical, Inc.

Copyright (C) 2012 PR Newswire. All rights reserved

...